PRISM BioLabLTD (206A) Stock Overview
A biotechnology company, discovers and develops small molecule inhibitors of protein-protein interaction targets utilizing proprietary PepMetics technology for treating patients suffering from cancer, fibrosis, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
206A Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
PRISM BioLab Co.,LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥177.00 |
| 52 Week High | JP¥330.00 |
| 52 Week Low | JP¥132.00 |
| Beta | 0 |
| 1 Month Change | 25.53% |
| 3 Month Change | -3.80% |
| 1 Year Change | -44.16% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.89% |
Recent News & Updates
Shareholder Returns
| 206A | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.7% | -2.5% | -0.6% |
| 1Y | -44.2% | 6.9% | 22.3% |
Return vs Industry: 206A underperformed the JP Pharmaceuticals industry which returned 6.9% over the past year.
Return vs Market: 206A underperformed the JP Market which returned 22.3% over the past year.
Price Volatility
| 206A volatility | |
|---|---|
| 206A Average Weekly Movement | 15.4% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.0% |
Stable Share Price: 206A's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 206A's weekly volatility has increased from 10% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 27 | Dai Takehara | prismbiolab.com |
PRISM BioLab Co.,LTD, a biotechnology company, discovers and develops small molecule inhibitors of protein-protein interaction targets utilizing proprietary PepMetics technology for treating patients suffering from cancer, fibrosis, and other diseases. The company develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has license agreements with Eisai Co., Ltd.
PRISM BioLab Co.,LTD Fundamentals Summary
| 206A fundamental statistics | |
|---|---|
| Market cap | JP¥6.49b |
| Earnings (TTM) | -JP¥833.00m |
| Revenue (TTM) | JP¥677.00m |
Is 206A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 206A income statement (TTM) | |
|---|---|
| Revenue | JP¥677.00m |
| Cost of Revenue | JP¥407.00m |
| Gross Profit | JP¥270.00m |
| Other Expenses | JP¥1.10b |
| Earnings | -JP¥833.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -22.72 |
| Gross Margin | 39.88% |
| Net Profit Margin | -123.04% |
| Debt/Equity Ratio | 0% |
How did 206A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/07 05:56 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PRISM BioLab Co.,LTD is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.